Regeneron Pharmaceuticals Inc

1. 01

   Set a 52-week high on 3 Nov 2026

   Closed at $973.36 on 3 Nov 2026: 0.2% below the 52-week high of $975.49 (3 Nov 2026) and 64.6% above the low of $591.52 (2 Jun 2026).

   Daily price bars, split-adjusted · as of 3 Nov 2026

2. 02

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +34.0% (SPY −2.6%, XLV +9.9%). 3 months: +28.0% (SPY −2.2%, XLV +13.5%). 1 year: +51.6% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: REGN, SPY and XLV · as of 3 Nov 2026

3. 03

   RSI(14) at 82.7, 70 or above

   The 14-session relative strength index closed at 82.7 on 3 Nov 2026, its 3rd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.

   Daily closes, split-adjusted; Wilder's 14-session RSI · as of 3 Nov 2026

4. 04

   P/E 49.5% below its peers' median

   Trailing P/E of 21.5 against a median of 42.6 across 4 peers named in its company record (range 30.9 to 115.7).

   Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026

5. 05

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $973.36 was 21.9% above its 50-day average ($798.74) and 31.6% above its 200-day average ($739.83). It has closed above the 200-day for 21 sessions, since 6 Oct 2026. The 50-day average crossed above the 200-day on 3 Sep 2026, 42 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

At the 3 Nov 2026 close